Gobin, Bérengère <br/><br/>
BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma.  [electronic resource] 

 -  International journal of cancer  Feb 2015 
 - 784-96 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0215 
<br/><br/><label>Standard No.: </label>10.1002/ijc.29040  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Bone Neoplasms--drug therapy<br/>Cell Line, Tumor<br/>Drug Synergism<br/>Female<br/>Humans<br/>Inhibitory Concentration 50<br/>Male<br/>Mice, Inbred C57BL<br/>Mice, Nude<br/>Osteoblasts--drug effects<br/>Osteoclasts--drug effects<br/>Osteosarcoma--drug therapy<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Thiazoles--administration & dosage<br/>Tumor Burden<br/>Xenograft Model Antitumor Assays